United Therapeutics Corporation (UTHR)

NASDAQ: UTHR · Real-Time Price · USD

608.49

+7.17 (1.19%)

Nov 4, 2026, 4:00 PM EST - Market closed

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Tyvaso Revenue	1.88B	1.88B	1.62B
Remodulin Revenue	502.90M	526.80M	538.10M
Orenitram Revenue	527.50M	496.90M	434.30M
Unituxin Revenue	233.40M	226.80M	238.70M
Adcirca Revenue	21.90M	30.00M	23.80M
Total Product Sales Revenue	3.18B	3.16B	2.86B
Revenue (Other)	6.60M	24.00M	22.10M
Revenue (Total)	3.19B	3.18B	2.88B

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
United States Revenue	3.04B	3.04B	2.74B
Rest-of-World Revenue	148.40M	145.70M	137.70M
Revenue (Total)	3.19B	3.18B	2.88B

Gross Profit

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Tyvaso Gross Profit	1.60B	1.64B	1.44B
Remodulin Gross Profit	445.30M	477.50M	490.70M
Orenitram Gross Profit	498.60M	468.20M	405.90M
Unituxin Gross Profit	215.40M	209.30M	224.30M
Adcirca Gross Profit	12.40M	16.90M	13.70M
Total Product Sales Gross Profit	2.77B	2.81B	2.57B
Gross Profit (Other)	-17.70M	-14.00M	-4.80M
Gross Profit (Total)	2.75B	2.80B	2.57B